Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Program FL9 is intended for laboratories that currently or will begin to perform minimal residual disease (MRD) testing (rare event analysis) for plasma cell myeloma.
- Two 4.5‑mL specimens containing a cell line/whole blood mixture simulating plasma cell myeloma minimal residual desease with clinical history and pertinent laboratory data
- One online case with clinical history and gated dot plots
This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.
- Shipment A: May 24
- Shipment B: November 22